Q/C TECHNOLOGIES, INC.

Listed Company

QCLSCIK 0001321834NasdaqNon-AcceleratedSmaller ReportingIn Vitro & In Vivo Diagnostic SubstancesDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-11.63M

Total Assets

—

Equity

—

Shares Out

7.85M

Op. Cash Flow

$-9.07M

Business

Q/C TECHNOLOGIES, INC. is a clinical-stage pharmaceutical company developing drug platforms to extend healthy lifespan, focused on two lead candidates: Isomyosamine and Supera-CBD. Its main offerings are Isomyosamine, an oral small molecule immunometabolic regulator targeting pro‑inflammatory cytokines for autoimmune and age‑related disorders (including sarcopenia and frailty), and Supera‑CBD, a synthetic CBD analog being developed for epilepsy, pain, addiction, and anxiety/depression. The company’s operations center on drug development, clinical trials, patent prosecution, licensing and strategic collaborations, and selective corporate investments. It pursues commercialization primarily in North America while relying on licensing, co‑promotion or partners for ex‑North America distribution and uses third‑party contractors for manufacturing and clinical development.

Summary from filing dated 2025-04-11

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Product Revenue	—	—	—	—	—
Product Cost of Sales	—	—	—	—	—
Gross Income	—	—	—	—	—
Administrative Expenses	4	4	5	6	6
Research and Development Expenses	3	3	8	9	7
Stock Based Compensation	2	1	3	695,191	—
Franchise Tax Expense	200,050	—	—	—	—
Series F-1 Warrant Issuance Expenses	—	539,097	—	—	—
Series G Warrant Issuance Expenses	—	969,505	—	—	—
Series H Warrant Issuance Expenses	264,417	—	—	—	—
Loss from Operations	−10	−10	−17	−15	−29
Interest and Dividend Income	−225,388	−351,809	−455,570	−83,991	−8,907
Gain on Sales of Marketable Securities	−2,176	−976	−416	—	—
Unrealized Gain on Marketable Securities	−38,671	−671	−514	−2,958	42,793
Impairment on Equity Investment	2	—	—	—	—
Change in fair value of Derivatives Liabilities	−983,000	388,000	−3	—	—
Change in fair value of Contingent Consideration	2	—	—	—	—
Change in fair value of Warrant Liabilities	—	4	−10	—	—
Loss on issuance of Series F-1 Convertible Preferred Stock	—	4	—	—	—
Loss on issuance of Series G Convertible Preferred Stock	—	5	—	—	—
Casualty Loss/(Gain)	—	−100,000	178,198	−4,442	—
Total Other (Income) Expenses	2	13	−13	−85,427	1
Loss Before Income Taxes	−12	−23	−4	−15	−30
Income Taxes	—	—	—	—	—
Net Loss	−12	−23	−4	−15	−30
Preferred Stock Dividends	3	4	4	—	—
Net Loss Attributable to Common Stockholders	−15	−27	−8	−15	—
Basic net loss per common share	−8.66	−1,081	−5.33	−11.74	−0.85
Diluted net loss per common share	−8.66	−1,081	−5.33	−11.74	—
Weighted average basic common stock outstanding	2	25,129	2	1	35
Weighted average diluted common stock outstanding	2	25,129	2	1	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and Cash Equivalents	986,996	173,154	3	749,090	555,967
Marketable Securities	15	8	2	4	11
Deposits and Other Receivables	18,200	—	—	—	—
Prepaid Expenses	774,095	893,730	893,226	565,787	1
Total Current Assets	17	9	6	5	13
Operating Lease Right-of-Use Assets	—	10,579	47,389	139,662	149,009
Intangible Assets	14	—	—	—	—
Goodwill	10	10	10	10	10
Investment in Oravax, Inc.	—	2	2	—	—
Total Non-Current Assets	25	12	12	12	12
Total Assets	41	21	18	18	25
Trade and Other Payables	2	3	4	3	986,626
Due to MyMD Florida Shareholders	29,982	29,982	—	—	—
Operating Lease Liability	—	10,579	48,870	65,780	53,240
Derivative Liabilities	2	1	61,000	—	—
Dividends Payable	365,970	2	265,019	—	—
License Fee Payable	533,744	—	—	—	—
Total Current Liabilities	6	7	5	3	1
Contingent Consideration Payable	11	—	—	—	—
Total Non-Current Liabilities	11	—	100,538	75,941	125,893
Total Liabilities	16	7	5	3	1
Commitments and Contingencies Note 8	—	—	—	—	—
Total Mezzanine Equity	3	5	—	—	—
Common Stock, par value $0.001, 1,250,000,000 shares authorized 7,690,403 and 33,636 shares issued and outstanding as of December 31, 2025 and December 31, 2024	184,502	3,364	2,019	1,316	102
Additional Paid in Capital	166	139	114	108	—
Accumulated Deficit	−144	−129	−102	−94	−79
Total Stockholders Equity	22	10	12	15	24
Total Liabilities and Stockholders Equity	41	21	18	18	25

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Gain on sale of marketable securities	−2,176	−976	−416	—	—
Change in fair value of marketable securities	−38,671	−671	—	—	—
Change in fair value of derivatives	−983,000	388,000	−3	—	—
Impairment of intangible assets	2	—	—	—	—
Options/RSUs issued to directors	1	476,563	944,834	—	—
Options/RSUs issued to key employees	104,506	507,390	2	338,922	—
Options/RSUs issued to non-employees	777,069	73,318	142,565	105,420	90,002
Shares issued for services	72,341	600,000	—	84,851	—
Accounts receivables	−18,200	—	—	—	—
Prepaid expenses	119,635	−504	−327,439	540,560	−912,815
Trade and other payables	−881,382	−814,114	1	2	−4
License fees payable	−838,227	—	—	—	—
Operating leases	—	−1,481	−578	1,917	−81
Deferred compensation payable	—	−100,538	100,538	—	—
Net cash used in operating activities	−9	−9	−13	−12	−20
Purchase of technology license	−2	—	—	—	—
Purchases of marketable securities	−19	−13	−13	−5	−13,403
Proceeds from sale of marketable securities	13	7	15	12	18
Net cash (used in investing activities	−8	−6	2	7	20
Net proceeds from the issuance of Series F Convertible Preferred Stock	—	—	15	—	—
Net proceeds from the issuance of Series F-1 Convertible Preferred Stock	—	5	15	—	—
Net proceeds from the issuance of Series G Convertible Preferred Stock	—	9	—	—	—
Net proceeds from the issuance of Series H Convertible Preferred Stock	7	—	—	—	—
Net proceeds from the exercise of warrants for common stock	12	—	—	—	—
Redemption of Convertible Preferred Stock	—	−73,472	−89,635	—	—
Dividend on Convertible Preferred Stock	−77,626	−1	−1	—	—
Premium on Convertible Preferred Stock	—	—	−77,090	—	—
Net cash provided by financing activities	18	13	13	6	73,533
Net increase/(decrease) in cash and cash equivalents	813,842	−3	2	193,123	407,683
Interest	—	—	—	13,322	271,800
Income Taxes	—	—	—	—	—
Fair value of Series G Convertible Preferred Stock issued in-lieu of dividends	2	—	—	—	—
Initial fair value of derivative liabilities pursuant to the issuance of Series H Convertible Preferred Stock and Warrants	2	—	—	—	—
Contingent Consideration Payable for the issuance of Series I Convertible Preferred Stock	9	—	—	—	—
Initial fair value of the LightSolver technology license	12	—	—	—	—
Initial fair value of warrant liabilities pursuant to the issuance of Series F-1 Convertible Preferred Stock and Warrants	—	8	—	—	—
Initial fair value of derivative liabilities pursuant to the issuance of Series F-1 Convertible Preferred Stock and Warrants	—	854,000	—	—	—
Initial fair value of warrant liabilities pursuant to the issuance of Series G Convertible Preferred Stock and Warrants	—	14	—	—	—
Reclass of warrant liability to equity upon warrant modification for the Series F Warrants	—	8	—	—	—
Reclass of warrant liability to equity upon warrant modification for the Series F-1 Warrants	—	7	—	—	—
Reclass of warrant liability to equity upon warrant modification for the Series G Warrants	—	12	—	—	—
Modification of Series F Convertible Preferred Stock	—	5	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro